Pharmaceutical

ASCO 2025: Multiple Domestic New Drugs Reveal Impressive Clinical Data ASCO Market Trend ASCO 2025 highlights impressive clinical data from multiple domestic new drugs including Kelun Biotech's sacituzumab govitecan, Mabwell's 9MW2821, Zelgen Bio's ZG006, and Hengrui's SHR-1501, showing promising efficacy and safety.
ASCO 2025: Innovent, RemeGen, Kelun Showcase Together! ASCO Market Trend ASCO 2025 highlights: Leading Chinese biotech companies Xinda, Rongchang, and Kelun present innovative clinical trial data on ADCs, bispecific antibodies, and targeted therapies, showcasing China's rising role in oncology innovation.
ASCO 2025: Most-Viewed Abstracts ASCO Cancer Oncology Market Trend Discover the top 4 most viewed abstracts at ASCO 2025, including updates on zanidatamab, talazoparib, GFH375, and Ziftomenib across gastric, prostate, solid tumors, and AML research.
ASCO 2025: Top 10 Clinical Breakthrough Oncology Products with Key Trial Results ASCO Cancer Oncology Market Trend Discover the top 10 clinical breakthrough oncology products presented at ASCO 2025, featuring innovative therapies from leading companies with promising efficacy and safety data in advanced cancers.
2025 ASCO: Chinese Pharma Innovations in Lung, Gastric, Blood & Thyroid Cancer Treatments ASCO Cancer Oncology Market Trend 2025 ASCO abstracts highlight breakthroughs by Chinese pharmaceutical companies across lung, gastric, hematologic, and thyroid cancers, showcasing innovation in targeted and combination therapies.
Biotech Cuts Jobs Despite $350M Funding Biotech Eikon Therapeutics Eikon Therapeutics raised $350M in 2025 to advance its drug pipeline, including Chinese-licensed assets, but recently announced a 15% layoff due to reduced U.S. research funding.
Genmab's Rina-S Shows Strong Data in Endometrial Cancer Genmab Genmab reports promising phase 1/2 results for Rina-S in advanced endometrial cancer, showing a 50% response rate and no major side effects, boosting confidence ahead of a planned phase 3 trial by late 2025.
GSK's Blenrep Gains EU Backing in New Combo Use GSK CHMP Blenrep Novatis GSK’s Blenrep gains CHMP recommendation for combination use in multiple myeloma, marking a comeback after U.S. withdrawal. Novartis withdraws Lutathera EU expansion. Other CHMP approvals and rejections detailed.
Trodelvy Shows Strong Solo Efficacy in TNBC Gilead Trodelvy Gilead’s Trodelvy shows significant solo efficacy in the ASCENT-03 trial, outperforming chemotherapy in previously untreated TNBC patients not eligible for immunotherapy.
PacBio Expands Long-Read Sequencing Presence in China Amid Illumina Ban PacBio Illumina Biotech PacBio strengthens its presence in China by expanding distribution of its hi-fi long-read sequencers with Haorui Gene, filling the gap left by Illumina’s import ban amid ongoing US-China trade tensions.